|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||555.72 g/mol|
|(what is this?)|
Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues, produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.
According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.
- Fusafungine at MeSH
- Daniel Levy; Aline Bluzat; Michel Seigneuret; Jean-Louis Rigaud (1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology. 50 (12 22): 2105–2107. doi:10.1016/0006-2952(95)02045-4. PMID 8849339.
- Lund, V. J.; Grouin, J. M.; Eccles, R; Bouter, C; Chabolle, F (2004). "Efficacy of fusafungine in acute rhinopharyngitis: A pooled analysis". Rhinology. 42 (4): 207–12. PMID 15626253.
- PRAC recommends that fusafungine nose and mouth sprays are no longer marketed
|This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|